3 Healthcare Stocks with ‘Strong Buy’ Analyst Ratings and ‘Perfect 10’ Smart Scores
Eli Lilly ($LLY), UnitedHealth ($UNH), and Gilead Sciences ($GILD) are three healthcare stocks with Strong Buy analyst ratings. All three stocks al...
Gilead Sciences Inc. (GILD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Squarepoint Ops LLC Maxime Fortin (Cio) | 820,732 | $122,330,105 | -55% | 0.13% |
| 2. | Bailard Inc Thomas Bailard | 734,720 | $109,510,135 | +1% | 2.22% |
| 3. | Fisher Asset Management Ken Fisher | 305,850 | $45,586,949 | +1517% | 0.01% |
| 4. | Impax Asset Management Ian Simm | 207,751 | $30,965,287 | -8% | 0.24% |
| 5. | Motley Fool Asset Management Bryan Hinmon | 104,926 | $15,639,220 | -3% | 0.59% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.92 | 10,000 | $999,150.00 | 88,173 | 2015-02-06 | Filing | |
| $43.05 | 10,000 | $430,493.00 | 69,458 | 2013-02-28 | Filing | |
| $44.00 | 10,000 | $439,955.00 | 26,097 | 2012-02-22 | Filing | |
| $38.60 | 8,704 | $335,974.40 | 12,800 | 2010-05-04 | Filing | |
| $38.59 | 4,096 | $158,064.64 | 4,096 | 2010-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $164.11 | 3,399 | $557,809.89 | 5,360 | 2026-11-06 | Filing | |
| $175.17 | 9,810 | $1,718,417.70 | 551,683 | 2026-11-05 | Filing | |
| $175.16 | 102,619 | $17,975,021.11 | 551,683 | 2026-11-04 | Filing | |
| $171.06 | 2,000 | $342,125.40 | 551,683 | 2026-11-02 | Filing | |
| $170.35 | 7,796 | $1,328,069.65 | 553,683 | 2026-11-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 30,190,640 | $4,485,711,723 | 0.23% | |
| 2. | 14,756,244 | $2,199,418,241 | 0.36% | |
| 3. | 11,259,657 | $1,678,251,875 | 0.34% | |
| 4. | 9,613,980 | $1,432,963,720 | 0.4% | |
| 5. | 7,799,464 | $1,162,634,058 | 0.21% |
News See All
Options Volatility and Implied Earnings Moves This Week, October 26 – October 30, 2026
This week, several major companies will be reporting earnings. Among them are Amazon (AMZN), Microsoft (MSFT), Alphabet Class A (GOOGL), Alphabet C...
Moderna (MRNA) vs. BioNTech (BNTX): Which Biotech Stock Offers Upside, According to Wall Street?
Moderna ($MRNA) and BioNTech ($BNTX) are biotech stocks focused on cancer vaccines as they enter their next growth phase. According to TipRanks Com...
Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?
Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on Astute Optics - US’s Substack. In this article, we will summarize the bulls’ thesis on GILD.
Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?
Biogen Inc. (NASDAQ:BIIB) closed at $225.71 on October 9.
Can Gilead (GILD) Stock Continue Rising in 2027?
Gilead Sciences, Inc. (NASDAQ:GILD) shares are up more than 24% this year, ahead of the S&P 500’s 14%. Gilead makes HIV, liver disease and cancer drugs.
Claude AI Portfolio: 8 Best-Performing Stocks in 2026
The use of AI for stock picking among retail and institutional investors is rising.
Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive?
Gilead Sciences, Inc. (NASDAQ:GILD) has had a considerably better year than the broader market.
Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?
Gilead Sciences, Inc. (NASDAQ:GILD) and Thermo Fisher Scientific Inc. (NYSE:TMO) are benefiting from two very different sources of growth.
10 Best Healthcare Stocks to Buy According to Hedge Funds
Healthcare has rarely been short of investment opportunities, but deciding where to look has become more complicated.
Hedge Fund Resource Center